Fundraising Fox
Digistain
YC S21London, GB · Founded 2019 · 40 employees · 4 known investors
Find your way into Digistain
Sign up to see every warm intro you have to Digistain
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Digistain team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Digistain develops imaging technology to grade breast cancer biopsies and assess cancer recurrence risk faster and more cost-effectively than traditional methods. The company serves breast oncologists and pathologists in clinical and diagnostic settings.
Founders & leadership· Y Combinator alumni (S21)
Digistain was founded in 2019 by Hemmel Amrania and Chris Phillips.
HA
Hemmel AmraniaCo-founder · Chief Executive OfficerHemmel Amrania holds a Ph.D. and has previously led businesses in therapeutics and diagnostics. He conducted doctoral research at Imperial College London and has led the research and clinical trial development for Digistain.
CP
Chris PhillipsFounderPhysics professor at Imperial College with research background in photovoltaics and biomedical imaging; co-developer of Digistain cancer diagnosis technology.
WH
Investors · 4
__Twitter.png)
Also in the syndicate · 1
Sofia Angels Ventures
Founder mafia
2 people who came through Digistain went on to found or lead other companies.
Related companies · 5
Spire HealthSpire Health provides continuous respiratory monitoring devices used by pulmonologists and patients to track lung disease. The company's sensors enable remote tracking of chronic respiratory conditions across the United States.
Shift LabsShift Labs develops DripAssist, an FDA-cleared infusion rate monitor that enables safe delivery of gravity IV medications in home and out-of-hospital settings. The platform remotely tracks medication infusion rates and provides data analytics for healthcare providers administering home infusion therapy.
ZenflowZenflow develops medical devices for treating benign prostatic hyperplasia (BPH) in men, founded from the Stanford Byers Center for Biodesign with a team experienced in medical device development and FDA regulation.
X-ZellX-ZELL develops cryoimmunostaining platforms and multiplex panels for cytology laboratories, enabling extraction of multiple biomarkers from single tissue specimens while preserving samples for further testing. The company serves pathologists, oncologists, and diagnostic partners primarily in Southeast Asia with CE-marked, ISO 13485-certified reagents and workflow solutions.
BodyportBodyport develops an FDA-cleared cardiac scale that non-invasively measures hemodynamic biomarkers through a patient's feet to detect early signs of worsening heart failure in a home setting. The company's platform pairs this hardware with a proprietary algorithm called the Congestion Index and a software system that integrates with electronic health records to enable remote patient monitoring and clinical decision support for heart failure management.
Companies working in the same space as Digistain.
Legal entities · 1
corporate structureDigistain Inc.
Companies House · registry record
View on Companies House ↗- Registered name
- DIGISTAIN LIMITED
- Company number
- 12329264
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 22 Nov 2019
- Registered office
- Unit 101, Interchange Business Park Howard Way, Interchange Park, Newport Pagnell, MK16 9PY
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 21 Nov 2025 · next due 5 Dec 2026
Current officers · 1
- Hemmel Amrania — director, appointed 22 Nov 2019
Source: Companies House public register · retrieved 24 Jul 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Digistain do?
- Digistain develops imaging technology to grade breast cancer biopsies and assess cancer recurrence risk faster and more cost-effectively than traditional methods. The company serves breast oncologists and pathologists in clinical and diagnostic settings.
- Who founded Digistain?
- Digistain was founded by Hemmel Amrania, Chris Phillips in 2019.
- Who are Digistain's investors?
- Digistain's investors include Gaingels, Oxford Technology Management, Y Combinator.
- Where is Digistain headquartered?
- Digistain is headquartered in London, GB.